Results 21 to 30 of about 52,753 (266)

Neuropsychiatric and Neurocognitive Manifestations in HIV-Infected Children Treated With Efavirenz in South Africa—A Retrospective Case Series

Frontiers in Neurology, 2019
Background: Efavirenz is associated with transient neuropsychiatric manifestations but the impact on neurocognition in children is unknown. Genetically slow metabolizers of efavirenz may be at risk of toxicity.
Charles K. Hammond, Charles K. Hammond, Brian Eley, Natalia Ing, Jo M. Wilmshurst   +4 more
doaj   +1 more source

Therapeutic activities of naringenin on efavirenz-induced sleep-like disorder in the midbrain of white albino mice [PDF]

Iranian Journal of Basic Medical Sciences, 2020
Objective(s): Efavirenz, has proven to be effective in suppressing human immunodeficiency virus (HIV) viral load; however, complaints of sleep disorders including hallucination, and insomnia have greatly contributed to non-adherence to antiretroviral ...
Olufunke Dosumu, Edidiong Akang, Oluwatomisin Faniyan, Alani Akanmu   +3 more
doaj   +1 more source

Nevirapine versus Efavirenz for patients co-infected with HIV and Tuberculosis: A Randomised Non-Inferiority Trial [PDF]

, 2013
BACKGROUND: In countries with a high incidence of HIV and tuberculosis co-infection, nevirapine and efavirenz are widely used as antiretroviral therapy but both interact with antituberculosis drugs. We aimed to compare efficacy and safety of a nevirapine-
Agnès Sobry, Alexandra Calmy, Anne-Marie Taburet, Avihingsanon, Blackwelder, Boulle, Carlota Silva, Chen, Christine Rouzioux, Christophe Michon, Cohen, Cohen, Davies, Dejesus, Dieterich, Elisabeth Baudin, Elizabete Nunes, Flandre, Ford, Gengiah, Gulick, Ilesh Jani, Kwara, Laura Ciaffi, Maartens, Manosuthi, Manosuthi, Maryline Bonnet, Matteelli, Mbuagbaw, Meintjes, Nilesh Bhatt, Rui Bastos, Scourfield, Shipton, Soriano, Swaminathan, Tang, Telenti, van Leth   +39 more
core   +3 more sources

Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.

New England Journal of Medicine, 2019
BACKGROUND An efavirenz-based regimen (with a 600-mg dose of efavirenz, known as EFV600) was the World Health Organization preferred first-line treatment for human immunodeficiency virus type 1 (HIV-1) infection until June 2018. Given concerns about side
C. Kouanfack, M. Mpoudi-Etame, P. O. Bassega, S. Eymard-Duvernay, Sandrine Leroy, S. Boyer, M. Peeters, A. Calmy, E. Delaporte   +8 more
semanticscholar   +1 more source

Design, Optimization, Manufacture and Characterization of Efavirenz-Loaded Flaxseed Oil Nanoemulsions

Pharmaceutics, 2020
The formation, manufacture and characterization of low energy water-in-oil (w/o) nanoemulsions prepared using cold pressed flaxseed oil containing efavirenz was investigated.
Priveledge Mazonde, S. Khamanga, R. B. Walker   +2 more
semanticscholar   +1 more source

Inclusion Compound of Efavirenz and γ-Cyclodextrin: Solid State Studies and Effect on Solubility

Molecules, 2021
Efavirenz is an antiretroviral drug of widespread use in the management of infections with human immunodeficiency virus type 1 (HIV-1). Efavirenz is also used in paediatrics, but due to its very poor aqueous solubility the liquid formulations available ...
S. Braga, F. El-Saleh, K. Lysenko, F. Paz   +3 more
semanticscholar   +1 more source

Efavirenz Pharmacogenetics and Weight Gain following Switch to Integrase Inhibitor-containing Regimens.

Clinical Infectious Diseases, 2020
BACKGROUND Unwanted weight gain affects some people living with HIV who are prescribed integrase strand transfer inhibitors (INSTI). Mechanisms and risk factors are incompletely understood.
Michael A Leonard, Zinhle Cindi, Y. Bradford, Kassem Bourgi, J. Koethe, M. Turner, Jamison Norwood, Beverly O. Woodward, Husamettin Erdem, Rebecca Basham, Paxton Baker, P. Rebeiro, T. Sterling, T. Hulgan, E. Daar, R. Gulick, S. Riddler, P. Sinxadi, M. Ritchie, D. Haas   +19 more
semanticscholar   +1 more source

Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial).

PLoS ONE, 2014
ObjectiveTo assess efavirenz plasma concentrations and their association with treatment efficacy and tolerance of efavirenz 600 mg daily in HIV-tuberculosis co-infected patients.MethodsHIV-infected adults with CD4+ T cell count ≤ 200/mm(3) received ...
Laurence Borand, Yoann Madec, Didier Laureillard, Monidarin Chou, Olivier Marcy, Phearavin Pheng, Narom Prak, Chindamony Kim, Khemarin Kim Lak, Chanroeun Hak, Bunnet Dim, Eric Nerrienet, Arnaud Fontanet, Thim Sok, Anne E Goldfeld, François-Xavier Blanc, Anne-Marie Taburet   +16 more
doaj   +1 more source

Personalizing HIV therapy, mission impossible? [PDF]

, 2012
Sustained HIV suppression depends on a number of factors including therapy adherence, management of side effects, viral resistance and individual characteristics of patients and therapeutic settings.
Hentig, Nils von
core   +1 more source

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz‐Containing Antiretroviral Therapy

Clinical pharmacology and therapy, 2019
The HIV type‐1 nonnucleoside reverse transcriptase inhibitor, efavirenz, is widely used to treat HIV type‐1 infection. Efavirenz is predominantly metabolized into inactive metabolites by cytochrome P450 (CYP)2B6, and patients with certain CYP2B6 genetic ...
Z. Desta, Roseann S. Gammal, L. Gong, Michelle Whirl‐Carrillo, A. Gaur, C. Sukasem, Jennifer K Hockings, Alan L. Myers, M. Swart, R. Tyndale, C. Masimirembwa, O. Iwuchukwu, S. Chirwa, J. Lennox, A. Gaedigk, T. Klein, D. Haas   +16 more
semanticscholar   +1 more source